Steady-state pharmacokinetics of oral ciprofloxacin in 3 continuous cycling peritoneal dialysis (CCPD) outpatients given ciprofloxacin 750 mg b.i.d. for 5 doses was determined. Mean steady-state maximum serum concentration and half-life were 4.4 ±1.5 mg/L and 10.3 ± 2.6 hours, respectively. Mean maximum dialysate concentration in the daytime long dwell and overnight continuous cycling dwell were 7.4 ± 1.2 mg/L and 3.3 ± 1.2 mg/L, respectively. Oral ciprofloxacin 750 mg b.i.d. may be reasonable for bloodstream and peritoneal infections caused by susceptible bacteria in CCPD patients.
MactierR.Peritonitis is still the achilles’ heel of peritoneal dialysis.Perit Dial Int2009; 29(3): 262–6.
2.
KolesnykI., DekkerF.W., BoeschotenE.W., KredietR.T.Time-dependent reasons for peritoneal dialysis technique failure and mortality.Perit Dial Int2010; 30(2): 170–7.
3.
MujaisS.Microbiology and outcomes of peritonitis in North America.Kidney Int Suppl2006; (103): S55–62.
4.
DavenportA.Peritonitis remains the major clinical complication of peritoneal dialysis: the London, UK, peritonitis audit 2002–2003.Pent Dial Int2009; 29(3): 297–302.
5.
KrishnanM., ThodisE., IkonomopoulosD., VidgenE., ChuM., BargmanJ.M.Predictors of outcome following bacterial peritonitis in peritoneal dialysis.Perit Dial Int2002; 22(5): 573–81.
ShalitI., GreenwoodR.B., MarksM.I., PedersonJ.A., FrederickD.L.Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis.Antimicrob Agents Chemother1986; 30(1): 152–6.
8.
FlemingL.W., MorelandT.A., ScottA.C., StewartW.K., WhiteL.O.Ciprofloxacin in plasma and peritoneal dialysate after oral therapy in patients on continuous ambulatory peritoneal dialysis.3 Antimicrob Chemother1981; 19(4): 493–503.
9.
TapsonJ.S., OrrK.E., GeorgeJ.C., StansfieldE., BintA.J., WardM.K.A comparison between oral ciprofloxacin and intraperitoneal vancomycin and netilmicin in CAPD peritonitis.3 Antimicrob Chemother1990; 26(Suppl F): 63–71.
10.
Bennett-JonesD.N., RussellG.I., BarrettA.A comparison between oral ciprofloxacin and intra-peritoneal vancomycin and gentamicin in the treatment of CAPD peritonitis.3 Antimicrob Chemother1990; 26(Suppl F): 73–6.
11.
BrophyD.F., MuellerB.A.Automated peritoneal dialysis: new implications for pharmacists.Ann Pharmacother1997; 31(6): 756–64.
12.
YeungS.M., WalkerS.E., TailorS.A., AwdishuL., TobeS., YassaT.Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis.Perit Dial Int2004; 24(5): 447–53.
13.
RegazziM.B., VillaniP., MaseratiR., CocchiL., GiacchinoR., BurroniD.Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV-1 infected individuals.Br J Clin Pharmacol1999; 47(4): 379–82.
14.
Asin-PrietoE., Rodriguez-GasconA., IslaA.Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents.J Infect Chemother2015; 21(5): 319–29.
15.
BlaserJ., StoneB.B., GronerM.C., ZinnerS.H.Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.Antimicrob Agents Chemother1987; 31(7): 1054–60.
16.
ZelenitskyS.A., HardingG.K., SunS., UbhiK., ArianoR.E.Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.J Antimicrob Chemother2003; 52(4): 668–74.
17.
Clinical and laboratory Standards Institute.M100 S26: performance standards for antimicrobial susceptibility testing, 26th ed; 2016 (Table 2B-1 Pseudomonas aeruginosa) [online.] Availabe from http://em100.edaptivedocs.net/GetDoc.aspx?doc=CLSI M100 S26:2016&scope=user. Last accessed August 18, 2016.
18.
ForrestA., NixD.E., BallowC.H., GossT.F., BirminghamM.C., SchentagJ.J.Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.Antimicrob Agents Chemother1993; 37(5): 1073–81.
19.
ForrestA., WeirM., PlaisanceK.I., DrusanoG.L., LeslieJ., StandifordH.C.Relationships between renal function and disposition of oral ciprofloxacin.Antimicrob Agents Chemother1988; 32(10): 1537–40.
20.
LipmanJ., ScribanteJ., GousA.G., HonH., TshukutsoaneS.Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath ciprofloxacin study group.Antimicrob Agents Chemother1998; 42(9): 2235–9.
21.
LiP.K., SzetoC.C., PirainoB., de ArteagaJ., FanS., FigueiredoA.E.ISPD peritonitis recommendations: 2016 update on prevention and treatment.Perit Dial Int2016; 36(5): 481–508.
